This study focuses on patients with hematological malignancy who experience bleeding problems after receiving intensive chemotherapy. These patients have low blood platelet counts and do not respond well to standard platelet transfusions. The study will test a treatment that combines human fibrinogen (a protein that helps blood clot) with platelet transfusions to help control bleeding.
The treatment being studied is called CLOTTAFACT, which contains human fibrinogen and is given through an intravenous injection. The purpose of the study is to see if adding fibrinogen to platelet transfusions can improve blood clotting in patients whose bodies don’t respond well to platelet transfusions alone. The study will measure how well the blood clots before and after receiving the combined treatment.
During the study, patients will receive fibrinogen followed by a platelet transfusion. Blood samples will be taken at different times to measure how well the treatment works. The study will also track any bleeding events or other health issues that occur during the treatment period. The amount of fibrinogen given will be based on the patient’s body weight, with a maximum single dose of 1.5 grams.
France 